Immune checkpoint blockade (ICB) is one of the primary methods of tumor immunotherapy. However, clinical data have shown that only a portion of patients respond to ICB treatment. Since the tumor's immune-suppressive environment plays a crucial role in ICB therapy, finding ways to effectively reshape this environment and increase the response rate to ICB treatment has become a key focus.
